The economic evaluation of pharmacotherapies for Parkinson's disease.
As well as the significant clinical effects of Parkinson's disease (PD), the disease places a high economic burden on society. Given the scarcity of health care resources, it is becoming increasingly necessary to demonstrate that new therapies for PD provide value for money in comparison with other potential interventions. This paper outlines the basic techniques of cost-effectiveness analysis and its application to PD. These techniques are illustrated by a recent economic evaluation of entacapone for use in Canada.
Coyle
D
D
Department of Medicine, Ottawa Health Research Institute, Ottawa Hospital, University of Ottawa, 1053 Carling Avenue, Ottawa, Ont, Canada K1Y 4E9. dcoyle@ohri.ca
Barbeau
M
M
Guttman
M
M
Baladi
J-F
JF
D000978:Antiparkinson Agents / Q000191:economics* / Q000627:therapeutic use; D002170:Canada; D002396:Catechols / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis / Q000379:methods; D016527:Drug Costs; D006801:Humans; D009570:Nitriles; D010300:Parkinson Disease / Q000188:drug therapy* / Q000191:economics
D000978:Antiparkinson Agents; D002396:Catechols; D009570:Nitriles; C071192:entacapone